58 results about "Vascular embolization" patented technology

A vascular implant formed of a compressible foam material has a compressed configuration from which it is expansible into a configuration substantially conforming to the shape and size of a vascular site to be embolized. Preferably, the implant is formed of a hydrophilic, macroporous foam material, having an initial configuration of a scaled-down model of the vascular site, from which it is compressible into the compressed configuration. The implant is made by scanning the vascular site to create a digitized scan data set; using the scan data set to create a three-dimensional digitized virtual model of the vascular site; using the virtual model to create a scaled-down physical mold of the vascular site; and using the mold to create a vascular implant in the form of a scaled-down model of the vascular site. To embolize a vascular site, the implant is compressed and passed through a microcatheter, the distal end of which has been passed into a vascular site. Upon entering the vascular site, the implant expands in situ substantially to fill the vascular site. A retention element is contained within the microcatheter and has a distal end detachably connected to the implant. A flexible, tubular deployment element is used to pass the implant and the retention element through the microcatheter, and then to separate the implant from the retention element when the implant has been passed out of the microcatheter and into the vascular site.

This invention provides an embolization material used for blocking a blood vessel in vivo for stopping the blood flow. The most suitable embolization material has a water swelling ratio of 30% or more, is degradable in a phosphate buffered saline, is formed as virtually spherical particles, and is preferably composed of a water insoluble poly(ethylene glycol) copolymer, wherein when the film formed from said polymer is saturated with water, it has an elastic modulus in tension of 1500 MPa or less. The embolization material of this invention can reliably block a blood vessel at an intended site without causing cohesion or clogging in a catheter or in the blood vessel at other than the intended site. Thereafter, the blocked site concerned can be liberated from the embolized state by degradation, and the degraded components can be metabolized or excreted outside the body.

The invention relates to a preparation method of a hydrogel rapidly crosslinked by enzyme catalysis, and application thereof. A precursor of the hydrogel consists of a mixture (hereinafter referred to as No. 1 solution) of good-biocompatibility macromonomer aqueous solution with an active phenolic hydroxyl unit and dioxygenase aqueous solution which is taken as a catalyst, and the aqueous solution of the precursor can rapidly react to form a 3D polymer cross-linked network after an oxidant (usually low-concentration oxydol, hereinafter referred to as No. 2 solution) is injected. As the No. 1 solution and the No. 2 solution have low-viscosity characteristic, are suitable for being transported and injected, and can rapidly crosslink to form a gel network, the hydrogel can be used for vascular embolization treatment, cancer treatment, family planning operation blocking agents, injectable tissue engineering scaffold materials, soft tissue fillers of human body, controlled release drug carriers, anti-adhesive membranes used in operations and the like after adding one or a plurality of components with specific properties to the No. 1 solution or the No. 2 solution or the gel network.

A resheathing apparatus for a tube that is insertable through an endovascular catheter includes a guide that has a proximal end, a distal end, at least one lumen extending from the proximal end to the distal end, and a branch extending away from the lumen at one end of the guide. A sheath may be placed over the tube by sliding the resheathing apparatus along the length of the tube. The resheathing apparatus may also include a guide tube that fits over the branch of the guide and directs a sheath over the tube that is insertable through an endovascular catheter. The resheathing apparatus may be used with vascular embolization devices, and may be used with devices that are delivered via microcatheter systems. Methods of using the resheathing apparatus are also disclosed.

The invention discloses a novel in situ liquid crystal vascular embolization agent, which mainly comprises a liquid crystal material, a water-soluble physiological acceptable solvent and water, wherein the ratio of mass parts of the liquid crystal material, the water-soluble solvent and the water is 0.3-3.2:1.2-2.1:0.5-1, and the mass percent of the water in the vascular embolization agent is less than 50%; and the liquid crystal material is of an amphiphilic polymer. The in situ liquid crystal vascular embolization agent has the effects of non-toxicity, non-adhesion, easy operation, safety, effectiveness and low cost, and the characteristics of good in vitro fluidity and fast sol-gel conversion speed.

The invention belongs to the technical field of medical polymer materials and in particular relates to X ray developing thermotropic hydrogel and a preparation method thereof. The X ray developing thermotropic hydrogel comprises an iodine-containing amphiphilic block copolymer and a solvent, wherein the iodine-containing amphiphilic block copolymer is obtained by bonding an iodine-containing micromolecule and an amphiphilic block copolymer by virtue of a covalent bond, and thermotropic gelatinization phase transformation can be carried out on a water system of the X ray developing thermotropic hydrogel along with temperature increase. The thermotropic hydrogel can be implanted under the skin and implanted into an abdominal cavity, an articular cavity and other specific parts of a human body in a mode of injection, and in situ formed hydrogel has good X ray developing performance, clear positioning and long-term tracing observation can be carried out on the hydrogel by adopting an X ray radiography technique. The thermotropic hydrogel also can serve as a medicine controlled release carrier, a tissue repairing support, a blood vascular embolization agent, a tissue marker and the like and can be used for realizing integration of diagnosis and treatment.

The invention discloses a biological decomposable developing micro sphere typed vascular plug material, which comprises the following parts: biological decomposable material, developing material without permeating X ray and antineoplastic agent, wherein the biological decomposable material parcels the particle structure of developing material and antineoplastic agent. The invention avoids excessive damage for organic, which can do MRI examination after plugging.

The invention relates to a carboxymethyl chitosan microsphere embolization agent. The embolization agent takes carboxymethyl chitosan as raw materials; the carboxymethyl chitosan is subjected to pretreatment, emulsification, cross-linking and dehydration drying to prepare microspheres with three-dimensional network structures. After the microspheres absorb water, the microspheres are smooth in surface and are rich in elasticity, have good biocompatibility and biodegradablity and is suitable for non-permanent vascular embolization.

A vascular embolization gelling agent for sustained release of drugs for treating tumors having a drug and a drug carrier. The drugs are antitumor drugs. The drug carrier includes poloxamer polymer and polyvinylpyrrolidone or gel made of the combination, and may be purified before use. The drug carrier accounts for 5-65% of the gel. The particle size of the gel is in the range of 10 nm-150 μm. The embolization agent is a liquid gel at normal temperature, to facilitate direct transcatheter injection, and is rapidly solidified to the gel state in body with the increase of the temperature; it is used to encapsulate different drugs on demand, and can achieve dual efficacy of embolization and drug treatment through local sustained release of the drug. The present invention can be used as the embolization agent for endovascular interventional therapy for transcatheter arterial chemoembolization of various benign and malignant tumors.

The invention discloses a biological decomposable developing micro sphere typed vascular plug material, which comprises the following parts: biological decomposable material, developing material without permeating X ray and antineoplastic agent. The invention is convenient to adjust time to do biological decomposition, which can do MRI examination after plugging.

An occlusion device for vascular surgery, suitable for clogging treatments of vascular entry sites and for endovascular interventions such as embolizations of blood vessels, treatment of arteriovenous malformations or small aneurysms, arterial dissections and the like, by releasing in an operation region a quick setting surgical glue or haemostatic fluid, through an outlet mouth of a duct. The device prevents the surgical glue from contacting within the duct a patient's biological fluids, in particular blood, which would close the duct. In the case of clogging treatments of vascular entry sites, a backflow preventing device may be provided, preferably provided by a coupling device between the duct and an introducer sheath by which an outlet mouth is kept in contact to keep in a one-way fluid tight contact against the outer surface of the introducer sheath until an injection pressure P2 is applied to cause release of the surgical glue.

The present invention discloses a multiple sustained release vascular embolization drug-loading composition. Release time of drugs from the composition is 1-360 d, and the drug-loading composition comprises a drug-loading microsphere made of a degradable material and/or a non-degradable material and a three-dimensional porous scaffold made of a degradable material and/or a non-degradable material.The three-dimensional porous scaffold has a uniform pore distribution and besides a pore diameter of pores is larger than a diameter of the drug-loading microsphere; the drug-containing drug-loadingmicrospheres pass through hydrogels or autologous coagulated blood blocks loaded in the three-dimensional porous scaffold, so that the drugs in the drug-loading microspheres are released from the drug-loading microspheres to the hydrogels or autologous coagulated blood blocks, then released into the three-dimensional porous scaffold and finally released outside the three-dimensional porous scaffold; or drug-free drug-loading microspheres are loaded into the three-dimensional porous scaffold to form a complex, then the drugs are loaded into the complex, and the drugs are released from the complex to the outside of the three-dimensional porous scaffold. The multiple sustained release vascular embolization drug-loading composition effectively solves a problem of drug burst release of the drug-loading microspheres.

The invention discloses a preparation method of drug-loadable polyvinyl alcohol eluted microspheres, and relates to the field of biological medicinal materials. Preparation comprises the following steps: (1) preparing a certain concentration of a polyvinyl alcohol aqueous solution, and then adding 2-acrylamide-2-methylpropanesulfonic acid and N,N-methylene bisacrylamide, and stirring evenly by magnetic force; and (2) with persulfate and sulfite as an oxidation-reduction initiation system and glutaraldehyde as a curing agent, preparing the modified polyvinyl alcohol microspheres with the particle size of 100-700 [mu]m by an inverse micro-suspension crosslinking method, namely the drug-loadable polyvinyl alcohol eluted microspheres. Because the microspheres contain a large number of sulfonic acid groups, the microspheres can be effectively loaded with positively charged drugs such as doxorubicin hydrochloride as vascular embolization agents.

The invention discloses a triblock copolymer by temperature induction and in-situ gelation, a method for preparing the triblock copolymer and an application of the triblock copolymer. The triblock copolymer comprises an ABA type and a BAB type, wherein, a section A is a polyN-isopropyl acrylamide; a section B is polymethacrylic acid-2-hydroxylethyl ester. The copolymer preparation process comprises the following steps that: the N-isopropyl acrylamide and the polymethacrylic acid-2-hydroxylethyl ester are used as monomers; m-2,5- dibromo adipate diethyl ester is used as a bifunctional initiator; and cuprous chloride, 1,4,8,11- tetramethyl-1,4,8,11-tetranitrogen heterocyclic ring tetradecane are used as a catalytic system; various compositions are prepared to a methanol solution and added into a mesonephric tube; oxygen in the system is removed by liquid nitrogen; and the ABA or the BAB type triblock copolymer is synthesized in the methanol solution at a temperature of 25 DEG C through feeding in sequence. The triblock copolymer, the method and the application have the advantages that: LCST(lower critical solution temperature) of the copolymer is controlled to between 26 and 34 DEG C, which is close to human temperature; the time for sol-gel transition is controlled within 60 minutes; and the copolymer has good biocompatibility and can be used as a vascular embolization material.

The invention belongs to the field of medical embolization devices, relates to a sodium alginate microsphere targeted vascular embolization agent containing an antineoplastic drug and a preparation method thereof. Alginic acid is taken as a pharmaceutical carrier, the antineoplastic drug etoposide is a pharmaceutical active ingredient, divalent metal cation or calcium ion solution is taken as a solidifying agent, and the sodium alginate encapsulates the etoposide to prepare ideal particle size-controllable sodium alginate microspheres comprising the etoposide, thus avoiding toxic side effect of traditional etoposide administration such as anaphylaxis and inconvenience. The vascular embolization agent changes the dosage form and route of administration way of the antineoplastic drug etoposide, has high efficacy and low toxicity, and is safely and effectively applied to clinical application. The vascular embolization agent has the advantages of mild preparation condition and simple and convenient operation, and is fit for large-scale production. The vascular embolization agent can be used for vascular embolization, local targeted tumor treatment, and treating small-cell carcinoma of the lung, oophoroma, carcinoma of testis, gastric cancer and liver cancer by administering the vascular embolization agent during operations.

A vascular embolization device having the function of administering a biochemical active material and also having high flexibility is provided. Specifically, the vascular embolization device includes a coil and a biochemical active material-containing resin wire inserted in the inside of the coil, in which the resin wire is a multilayer strand including a core and at least one outer layer, and the core and the at least one outer layer individually include resin compositions with solubilities different from each other in the same organic solvent.

The invention discloses a continuous acting vascular clamp. The continuous acting vascular clamp comprises an upper clamp body, a flexible body and a lower clamp body. The continuous acting vascular clamp can be freely opened or closed and can be opened to reach an included angle of 90 degrees, thus the vessel is easily aligned, and the vessel is particularly conveniently clamped and closed during minimally invasive surgery; two ends are fixed and parallel during clamping, so that the clamping force can be parallel and balanced; the clamp can be reversely buckled to be self-locked, and therefore, the vessel can be firmly closed; the clamp can be used in match with an automatic continuous acting plastic clamp, the a plurality of vessels can be continuously clamped to be closed; the clamp is prepared from an absorbable material or non-absorbable polymer synthesis material which can be implanted into a human body for a long term; due to be prepared from a biodegradable material which can be implanted into the human body for a long term, the clamp can be completely absorbed by the human body without residue after permanent vascular embolization, and therefore, the tissue adhesion or obstruction possibly caused by non-absorbable vascular clamp can be effectively avoided.

The invention discloses a preparation method of high-drug-loading degradable alginate sulfate vascular embolization microspheres. The preparation method comprises the following steps of: S01, preparing an aqueous phase; S02, preparing an oil phase; S03, preparing alginate sulfate microspheres; and S04, preparing drug-loaded alginate sulfate embolization microspheres. The invention also discloses the high-drug-loading degradable alginate sulfate vascular embolization microspheres obtained by the preparation method of the high-drug-loading degradable alginate sulfate vascular embolization microspheres and application of the high-drug-loading degradable alginate sulfate vascular embolization microspheres in preparation of an embolization agent for transcatheter arterial chemoembolization treatment. The alginate sulfate vascular embolization microspheres disclosed by the invention have good biocompatibility and are biodegradable, and the degradation product is safe and non-toxic. The preparation method has the advantages of simplicity and convenience in operation, high repeatability, mild conditions and the like, the prepared microspheres are uniform and controllable in particle size, and the vascular embolization microspheres prepared by the invention have good application prospects in the field of tumor interventional therapy.

A vascular embolization device comprises an elongated coil having a lumen, said coil and lumen being at least partially embedded in an elongated foam member comprising a flexible, biodegradable, water insoluble, open, interconnecting-cell foam material having embolic characteristics, and capable of allowing cell proliferation into the open cell foam interior. A manufacturing method is disclosed.

The present invention describes a process for the synthesis of spherical particles of polyvinyl alcohol—PVA and/or polyvinyl acetate—PVAc with shell nucleus structure from total or partial hydrolysis in a caustic aqueous medium with obtaining particulates of PVA/PVAc with controlled spherical morphology, to be used in vascular embolization.

The invention discloses a heparin starch microsphere vascular embolizing agent with anti-tumor effect and a preparation method thereof, which belong to the field of pharmaceutical and chemical industry, and concretely relates to the heparin starch microsphere vascular embolizing agent and the preparation method thereof. The technical problem to be solved by the present invention is to provide a heparin starch microsphere vascular embolization agent and the preparation method thereof. The method prepares heparin starch microspheres with controlled size and uniform particle size by introducing heparin with good biocompatibility and capable of inhibiting tumor growth and metastasis. The heparin starch microspheres not only have an embolization effect, but also inhibits tumor growth and metastasis, and achieves the purpose of treating cancer. The method has the advantages of simple operation, good repeatability and low temperature requirement, can prepare the heparin starch microspheres with good biocompatibility, degradability and no toxic side effects by controlling reaction conditions, can be widely used in tumor vascular embolization and treatment, and establishes a foundation forits application in the medical field.

The purpose of the present invention is to provide an injectable sol into a body, suited for delivery through a catheter, and usable for tissue perforation closure, ulcer protection, or vascular embolization. Provided are a sol for tissue perforation closure, a sol for ulcer protection, and a sol for vascular embolization, each containing from 0.6 mass % to 3 mass % of a collagen, water, from 200 mM to 330 mM sodium chloride, and a buffer and having a pH from 6.0 to 9.0.

The invention belongs to the field of medical embolization equipment, and relates to a composite matrix gel vascular embolization agent and a preparation method thereof. According to the composite matrix gel vascular embolization agent, alginate and chitosan are taken as preparation materials of a gel; by adopting a composite matrix hydrogel, the problems that a pure calcium alginate microsphere embolization agent is unstable at a blood plasma environment, is easy to break, and can cause short embolization effect maintaining time can be solved; and the composite matrix hydrogel prepared from sodium alginate and chitosan can be used for stabilizing the strength of the gel in blood vessels, can be taken as a vascular embolization agent to exert continuous vascular embolization functions, has high efficiency and low toxicity, can be clinically applied, and also is safe and effective. The composite matrix gel vascular embolization agent disclosed by the invention is mild in preparation condition and simple and convenient to operate, is suitable for scale production, can be applied to vascular embolization, can be applied to local targeted therapy of tumors such as liver cancer, kidney cancer, small cell lung cancer, ovarian cancer and testicular cancer, and can also be used for treating hyperthyroidism diseases and internal hemorrhage diseases.

The invention discloses a pH-reduction dual-response polymer embolization agent for tumor catheter-free embolization and synthesis thereof. The embolization agent is a linear triblock polymer; the pHand reduction stimulation response chain segment is formed by copolymerization of a monomer unit with a carboxyl side group and a monomer unit with a sulfydryl side group in the same structure, or isformed by copolymerization of a monomer unit with a carboxyl side group, a monomer unit with a sulfydryl side group and a monomer unit with a phenolic hydroxyl side group in the same structure. Then the polymer and sulfydryl-containing water-soluble small molecules are oxidized by using an oxidant to form disulfide bonds; and B is a hydrophilic polymer chain segment. An initiator initiates the monomers to polymerize into a pH-responsive adjustable polymer by the initiator; oxidation is performed to construct a disulfide bond with reduction response; and the pH-reduction dual-response polymer embolization agent for tumor catheter-free embolization. The embolization agent can respond to tumor reducibility and a subacid microenvironment to generate gelation transformation, so that the vascular embolization effect on tumors is realized.